Abstract
Genetic factors are important in hypertension pathophysiology and several genes and polymorphisms that predispose to hypertension and its complications have been identified by genome-wide association studies. However, there are limited hypertension genome-wide and candidate-gene association studies in Asia, and the majority come from East Asian countries. Most of the polymorphisms identified are identical to those in European populations and more studies are needed. Hypertension polygenic risk scores are being evaluated for identification of hypertension risk and early aggressive management. Generalized and abdominal obesity are important hypertension risk factors and are widely prevalent in most Asian countries. Asia-specific hypertension pharmacogenomics and other management strategies, including technology, need further evaluation. A social determinants approach to hypertension management is important to ameliorate multiple hypertension risk factors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ehret GB. Genetics of hypertension. In: Bakris GL, Sorrentino MJ, editors. Hypertension: a companion to Braunwald’s heart disease. Philadelphia: Elsevier; 2018. p. 52–9.
Milford DV. Investigation of hypertension and the recognition of monogenic hypertension. Arch Dis Child. 1999;81(5):452–5.
Luft FC. Monogenic hypertension: lessons from the genome. Kidney Int. 2001;60:381–90.
Simonetti GD, Mohaupt MG, Bianchetti MG. Monogenic forms of hypertension. Eur J Pediatr. 2012;171(10):1433–9.
Kurland L, Liljedahl U, Lind L. Hypertension and SNP genotyping in antihypertensive treatment. Cardiovasc Toxicol. 2005;5(2):133–42.
Doris PA. Hypertension genetics, single nucleotide polymorphisms, and the common disease: common variant hypothesis. Hypertension. 2002;39(2 Pt 2):323–31.
Kotchen TA. Hypertensive vascular disease. In: Jameson JL, Fauci AS, Kasper DL, et al., editors. Harrison’ principles of internal medicine. 20th ed. New York: McGraw Hill; 2018. p. 1890–906.
Padmanabhan S, Dominiczak AF. Genomics of hypertension: the road to precision medicine. Nat Rev Cardiol. 2021;18:235–50.
Lip S, Padmanabhan S. Genomics of blood pressure and hypertension: extending the mosaic theory toward stratification. Can J Cardiol. 2020;36:694–705.
Sharma S. Hypertension gene risk score in diagnosis and prediction of complications. RUHS J Health Sci. 2021;6:53–62.
Xi B, Shen Y, Reilly KH, Wang X, Mi J. Recapit ulation of four hypertension susceptibility genes (CSK, CYP17A1, MTHFR, FGF5) in east Asians. Metabolism. 2013;62:196–203.
Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in East Asians. Nat Genet. 2011 Jun;43(6):531–8.
Kato N, Loh M, Takeuchi F, Verweij N, Wang X, Zhang W, et al. Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nat Genet. 2015;47(11):1282–93.
Wang Y, Wang JG. Genome-wide association studies of hypertension and several other cardiovascular diseases. Pulse (Basel). 2019;6:169–86.
Hong KW, Go MJ, Jin HS, Lim JE, Lee JY, Han BG, et al. Genetic variations in ATP2B1, CSK, ARSG and CSMD1 loci are related to blood pressure and/or hypertension in two Korean cohorts. J Hum Hypertens. 2010;24:367–72.
Tabara Y, Kohara K, Miki T, Millennium Genome Project for Hypertension. Hunting for genes of hypertension: the Millennium Genome Project for Hypertension. Hypertens Res. 2012;35:567–73.
Kato N, Loh M, Takeuchi F, Verweij N, Wang X, Zhang W, et al. Trans-ancestry geneome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nat Genet. 2015;47:1282–93.
Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412–25.
Torkmani A, Wineinger NE, Topol E. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19:581–90.
Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. International Consortium for Blood Pressure Genome-Wide Association Studies. Nature. 2011;478:103–9.
Mars N, Koskela JT, Ripatti P, Kiiskinen TTJ, Havulinna AS, Lindbohm JV, et al. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat Med. 2020;26:549–57.
Kullo IJ, Dikilitas O. Polygenic risk scores for diverse ancestries. J Am Coll Cardiol. 2020;76:715–8.
G B, Sharma S. Hypertension gene risk score and influence of physical activity on cardiovascular risk in hypertension: Mendelian randomization study. PhD Thesis, Rajasthan University of Health Sciences, Jaipur; 2021.
Wang M, Menon R, Mishra S, Patel AP, Chaffin M, Tanneeru D, et al. Validation of a genome-wide polygenic risk score for coronary artery disease in South Asians. J Am Coll Cardiol. 2020;76:703–14.
Paul S, INDIGENIUS Consortium. Report submitted to Indian Council of Medical Research; 2021.
Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, et al. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother. 2022;8:85.
Parsa A, Kao WHL, Xie D, Astor BC, Li M, Hsu CY, et al. APOL1 risk variants, race and progression of chronic kidney disease. N Engl J Med. 2013;369:2183–96.
Lynch AI, Eckfeldt JH, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, et al. Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study. Pharmacogenet Genomics. 2012;22:355–66.
Gupta R, Wood DA. Primary prevention of ischemic heart disease: populations, individuals and healthcare professionals. Lancet. 2019;394:685–96.
Landsberg L. Obesity. In: Bakris GL, Sorrentino MJ, editors. Hypertension: a companion to Braunwald’s heart disease. Philadelphia: Elsevier; 2018. p. 328–34.
NCD Risk Factor Collaboration (NCD-RiSC). Rising rural body-mass index is the main driver of global obesity epidemic in adults. Nature. 2019;569:260–4.
Kushner RF. Evaluation and management of obesity. In: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s principles of internal medicine. 20th ed. New York: McGraw Hill; 2018. p. 2843–50.
Misra A, Jayawardene R, Anoop S. Obesity in South Asia: phenotype, morbidities and mitigation. Curr Obes Rep. 2019;8:43–52.
Guptha LS. A cross-sectional epidemiology study of the relationships between body mass index and the risk of diabetes, and diabetes and the QRISK2 10-Year cardiovascular risk score using India Heart Watch data. PhD thesis, Trident University International, San Diego; 2021. https://www.proquest.com/openview/8d3d1772bfee8ca075388311d98982e7/1?pq-origsite=gscholar&cbl=18750&diss=y. Accessed 26 Jun 2021.
Victor RG. Systemic hypertension: mechanisms and diagnosis. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, editors. Braunwald’s heart disease. 11th ed. New Delhi: Elsevier; 2019. p. 910–27.
Wang C, Fu W, Cao S, Xu H, Tian Q, Gan Y, et al. Association of adiposity indicators with hypertension among Chinese adults. Nutr Metab Cardiovasc Dis. 2021;31:1391–400.
Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, et al. Association between body mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011;364:719–29.
Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395:795–808.
Ford ND, Patel SA, Venkat Narayan KM. Obesity in low and middle-income countries: burden, drivers and emerging challenges. Annu Rev Public Health. 2017;38:145–64.
Apóstolo J, Cooke R, Bobrowicz-Campos E, Santana S, Marcucci M, Cano A, et al. Predicting risk and outcomes for frail older adults : an umbrella review of frailty screening tools. JBI Database Syst Rev Implement Rep. 2017;15:1154–208.
Hu K, Zhou Q, Jiang Y, Shang Z, Mei F, Gao Q, et al. Association between frailty and mortality, falls and hospitalization among patients with hypertension: a systematic review and meta-analysis. Biomed Res Int. 2021;2021:2690296.
Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A call to action and a life-course strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on Hypertension. Lancet. 2016;388:2665–712.
Tronieri JS, Wadden TA, Chao AM, Tsai AG. Primary care interventions for obesity: review of the evidence. Curr Obes Rep. 2019;8:128–36.
Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.
LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA. Behavioural and pharmacotherapy weight loss interventions to prevent obesity related morbidity and mortality in adults: an updated systematic review for the US Preventive Services Task Force. Report No. 18-05239-EF-1. Rockville: Agency for Healthcare Research and Quality (US); 2018.
Srivastava G, Apovian CL. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;4:12–24.
NCD Countdown 2030 Collaborators. NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4. Lancet. 2020;396:918–34.
Gupta R, Yusuf S. Challenges in management and prevention of ischemic heart disease in low socioeconomic status people in LLMICs. BMC Med. 2019;17(1):209.
Jeemon P, Gupta R, Onen C, Adler A, Gaziano TA, Prabhakaran D, et al. Management of hypertension and dyslipidemia for primary prevention of cardiovascular diseases. In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, editors. Cardiovascular, respiratory, and related disorders, Chap. 22. 3rd ed. Washington, DC: The World Bank; 2017.
Gupta R, Yusuf S. Towards better hypertension management in India. Indian J Med Res. 2014;139(5):657–60.
Bhavnani SP, Parakh K, Atrej A, Druz R, Graham GN, Hayek SS, et al. Roadmap for innovation- ACC health policy statement of healthcare transformation in the era of digital big data and precision health: a report of the American College of Cardiology Task Force on health policy statements and systems of care. J Am Coll Cardiol. 2017;2017(70):2696–718.
Gupta R, Gupta S. Social determinants’ approach for hypertension control. In: CVS R, editor. Cardiological Society of India: hypertension reviews 2020. Noida: Incessant Nature Science Publishers; 2020. p. 11–21.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Gupta, R. (2022). Relation of Genetics and Obesity with Hypertension: An Asian Perspective. In: Ram, C.V.S., Teo, B.W.J., Wander, G.S. (eds) Hypertension and Cardiovascular Disease in Asia. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-030-95734-6_6
Download citation
DOI: https://doi.org/10.1007/978-3-030-95734-6_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-95733-9
Online ISBN: 978-3-030-95734-6
eBook Packages: MedicineMedicine (R0)